AR064208A1 - DERIVATIVES OF PIRIDIN-3-IL-QUINAZOLINAS AS INHIBITORS OF B-RAF. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. - Google Patents
DERIVATIVES OF PIRIDIN-3-IL-QUINAZOLINAS AS INHIBITORS OF B-RAF. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.Info
- Publication number
- AR064208A1 AR064208A1 ARP070105508A ARP070105508A AR064208A1 AR 064208 A1 AR064208 A1 AR 064208A1 AR P070105508 A ARP070105508 A AR P070105508A AR P070105508 A ARP070105508 A AR P070105508A AR 064208 A1 AR064208 A1 AR 064208A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbamoyl
- amino
- sulfamoyl
- carbocyclyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 title 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 34
- -1 nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl Chemical group 0.000 abstract 22
- 229910052757 nitrogen Inorganic materials 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 5
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 4
- 125000001589 carboacyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Procesos para la elaboracion de dichos compuestos químicos, con composiciones farmacéuticas que los contienen y con su uso en la elaboracion de medicamentos para la produccion de un efecto anticanceroso en un animal de sangre caliente, tal como el hombre. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), en donde: R1 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoílo, mercapto, sulfamoílo, ureido, alquilo C1-6, alquenilo C2- 6, alquinilo C2-6, aIcoxi C1-6, alcanoílo C1-6, alcanoiloxi C1-6, N-(C1-6 alquil)amino, N,N-(C1-6 alquil)2amino, N'-(C1-6 alquil)ureido, N',N'-(C1-6 aIquil)2ureido, N'-(C1-6 alquil)-N-(C1-6 aIquil)ureido, N',N'-(C1-6 aIquil)2-N-(C1-6 aIquil)ureido, alcanoilamino C1-6, N-(C1-6 alquil)C1-6alcanoilamino, N-(C1-6 alquiI)carbamoilo, N,N-(C1-6 aIquil)2carbamoilo, alquiI C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(C1-6 alquil)sulfamoilo, N,N-(C1-6 alquiI)2sulfamoilo, alquilsulfonilamino C1-6, (R20)(R21)P(O)-, (R27)(R28)P(O)NH-, (R29)(R30)P(O)(C1-6 aIquil)N-, (R24)(R25)(R26)Si-, carbociclil-R3- y heterociclil-R4-; en donde R1 puede estar opcionalmente sustituido sobre carbono con uno o más R5; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede estar opcionalmente sustituido con un grupo seleccionado entre R6; n se selecciona entre 0-4; en donde los valores de R1 pueden ser iguales o diferentes; R2 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aIcoxi C1-6, alcanoílo C1-6, alcanoiloxi C1-6, N-(C1-6 alquil)amino, N,N-(C1-6 alquil)2amino, alcanoilamino C1-6, N-(C1-6 alquiI)carbamoilo, N,N-(C1-6 aIquil)2carbamoilo, alquiI C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(C1-6 alquil)sulfamoilo, N,N-(C1-6 alquiI)2sulfamoilo, alquilsulfonilamino C1-6, carbociclil-R7- y heterociclil-R8-; en donde R2 puede estar opcionalmente sustituido sobre carbono con uno o más R9; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede estar opcionalmente sustituido con un grupo seleccionado entre R10; m se selecciona entre 0-4; en donde los valores de R2 pueden ser iguales o diferentes; R5 y R9 se seleccionan en forma independiente entre halo, nitro, ciano. hidroxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aIcoxi C1-6, alcanoílo C1-6, alcanoiloxi C1-6, N-(C1-6 alquil)amino, N,N-(C1-6 alquil)2amino, alcanoilamino C1-6, N-(C1-6 alquil)C1-6 alcanoilamino, N-(C1-6 alquiI)carbamoilo, N,N-(C1-6 aIquil)2carbamoilo, alquiI C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, alcoxicarbonilamino C1-6, N-(C1-6 alquil)sulfamoilo, N,N-(C1-6 alquiI)2sulfamoilo, alquilsulfonilamino C1-6, (R22)(R23)P(O)-, (R32)(R32)P(O)NH-, (R33)(R34)P(O)(C1-6 alquil)N-, carbociclil-R11- y heterociclil-R12-; en donde R5 y R9 en forma independiente entre sí pueden estar sustituidos opcionalmente sobre carbono con uno o más R13; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede estar opcionalmente sustituido con un grupo seleccionado entre R14; R3, R4, R7, R8, R11 y R12 se seleccionan en forma independiente entre un enlace directo, -O-, -N(R15)-, -C(O)-, -N(R16)C(O)-, -C(O)N(R17)-, -S(O)s-, -SO2N(R18)- y -N(R19)SO2-; en donde R15, R16, R17, R18 y R19 es hidrogeno, alcoxicarbonilo C1-6 o alquilo C1-6 y s es 0-2; R6, R10 y R14 se seleccionan en forma independiente entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(C1-6alquil)carbamoilo, N,N-(C1-6 alquil)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R20, R21, R22, R23, R27, R28, R29, R30, R31, R32, R33, y R34 se seleccionan en forma independiente entre amino, alquilo C1-6, alcoxi C1-6 y carbociclilo; R24, R25 y R26 se seleccionan en forma independiente entre hidroxi, alquilo C1-6, alcoxi C1-6 y carbociclilo; o R24 y R25 junto con el silicio al cual se encuentran unidos forman un anillo; en donde R24, R25 y R26 se pueden sustituir opcionalmente en forma independiente sobre carbono con uno o más R35; R13 y R35 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N-etilamino, acetilamino, N-metilcarbamoilo, N-etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N-metilsulfamoilo, N-etilsulfamoilo, N,N-dimetilsulfamoilo, NN-dietilsulfamoilo y N-metil-N-etilsulfamoilo; o una sal aceptable para uso farmacéutico del mismo.Processes for the elaboration of said chemical compounds, with pharmaceutical compositions that contain them and with their use in the elaboration of medicines for the production of an anticancer effect in a warm-blooded animal, such as man. Claim 1: A compound characterized in that it has the formula (1), wherein: R1 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, C1-6 alkyl, C2 alkenyl - 6, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkanoyl, C1-6 alkanoyloxy, N- (C1-6 alkyl) amino, N, N- (C1-6 alkyl) 2amino, N '- (C1 -6 alkyl) ureido, N ', N' - (C1-6 alkyl) 2ureido, N '- (C1-6 alkyl) -N- (C1-6 alkyl) ureido, N', N '- (C1-6 alkyl) 2-N- (C1-6 alkyl) ureido, C1-6 alkanoylamino, N- (C1-6 alkyl) C1-6 alkanoylamino, N- (C1-6 alkyl) carbamoyl, N, N- (C1-6 alkyl) ) 2carbamoyl, C1-6S alkyl (O) a where a is between 0 and 2, C1-6 alkoxycarbonyl, N- (C1-6 alkyl) sulfamoyl, N, N- (C1-6 alkyl) 2sulfamoyl, C1- alkylsulfonylamino 6, (R20) (R21) P (O) -, (R27) (R28) P (O) NH-, (R29) (R30) P (O) (C1-6 alkyl) N-, (R24) ( R25) (R26) Si-, carbocyclyl-R3- and heterocyclyl-R4-; wherein R1 may be optionally substituted on carbon with one or more R5; and wherein if said heterocyclyl contains a portion -NH- said nitrogen may be optionally substituted with a group selected from R6; n is selected from 0-4; where the values of R1 can be the same or different; R2 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkanoyl, alkanoyloxy C1-6, N- (C1-6 alkyl) amino, N, N- (C1-6 alkyl) 2amino, C1-6 alkanoylamino, N- (C1-6 alkyl) carbamoyl, N, N- (C1-6 alkyl) ) 2carbamoyl, C1-6S alkyl (O) a where a is between 0 and 2, C1-6 alkoxycarbonyl, N- (C1-6 alkyl) sulfamoyl, N, N- (C1-6 alkyl) 2sulfamoyl, C1- alkylsulfonylamino 6, carbocyclyl-R7- and heterocyclyl-R8-; wherein R2 may be optionally substituted on carbon with one or more R9; and wherein if said heterocyclyl contains a portion -NH- said nitrogen may be optionally substituted with a group selected from R10; m is selected from 0-4; where R2 values may be the same or different; R5 and R9 are independently selected from halo, nitro, cyano. hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N- (C 1-6 alkyl) amino, N, N- (C1-6 alkyl) 2amino, C1-6 alkanoylamino, N- (C1-6 alkyl) C1-6 alkanoylamino, N- (C1-6 alkyl) carbamoyl, N, N- (C1-6 alkyl) 2carbamoyl, C1-6S alkyl (O) a where a is between 0 and 2, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, N- (C1-6 alkyl) sulfamoyl, N, N- (C1-6 alkyl ) 2sulfamoyl, C1-6 alkylsulfonylamino, (R22) (R23) P (O) -, (R32) (R32) P (O) NH-, (R33) (R34) P (O) (C1-6 alkyl) N -, carbocyclyl-R11- and heterocyclyl-R12-; wherein R5 and R9 independently of each other may optionally be substituted on carbon with one or more R13; and wherein if said heterocyclyl contains a portion -NH- said nitrogen may be optionally substituted with a group selected from R14; R3, R4, R7, R8, R11 and R12 are independently selected from a direct link, -O-, -N (R15) -, -C (O) -, -N (R16) C (O) -, -C (O) N (R17) -, -S (O) s-, -SO2N (R18) - and -N (R19) SO2-; wherein R15, R16, R17, R18 and R19 is hydrogen, C1-6 alkoxycarbonyl or C1-6 alkyl and s is 0-2; R6, R10 and R14 are independently selected from C1-6 alkyl, C1-6 alkanoyl, C1-6 alkylsulfonyl, C1-6 alkoxycarbonyl, carbamoyl, N- (C1-6 alkyl) carbamoyl, N, N- (C1-6 alkyl) carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; R20, R21, R22, R23, R27, R28, R29, R30, R31, R32, R33, and R34 are independently selected from amino, C1-6 alkyl, C1-6 alkoxy and carbocyclyl; R24, R25 and R26 are independently selected from hydroxy, C1-6 alkyl, C1-6 alkoxy and carbocyclyl; or R24 and R25 together with the silicon to which they are attached form a ring; wherein R24, R25 and R26 can optionally be independently substituted on carbon with one or more R35; R13 and R35 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino , N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl , methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N, N-dimethylsulfamoyl, NN-diethylsulfamoyl and N-methyl-N-ethylsulfamoyl; or a salt acceptable for pharmaceutical use thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86924106P | 2006-12-08 | 2006-12-08 | |
| US98573207P | 2007-11-06 | 2007-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064208A1 true AR064208A1 (en) | 2009-03-18 |
Family
ID=39386079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105508A AR064208A1 (en) | 2006-12-08 | 2007-12-07 | DERIVATIVES OF PIRIDIN-3-IL-QUINAZOLINAS AS INHIBITORS OF B-RAF. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR064208A1 (en) |
| CL (1) | CL2007003557A1 (en) |
| PE (1) | PE20081351A1 (en) |
| TW (1) | TW200829566A (en) |
| WO (1) | WO2008068507A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Fast Dissociting Dopamine 2 Receptor Antagonists |
| US20100216767A1 (en) * | 2006-12-22 | 2010-08-26 | Mina Aikawa | Quinazolines for pdk1 inhibition |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Fast -Dissociating Dopamine 2 Receptor Antagonists |
| CN101663292A (en) | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 4-Alkoxypyridazine derivatives as rapidly dissociating dopamine 2 receptor antagonists |
| MX2009011416A (en) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists. |
| AU2009275887B2 (en) | 2008-07-31 | 2013-06-20 | Janssen Pharmaceutica Nv | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
| PE20120110A1 (en) | 2009-02-13 | 2012-02-20 | Fovea Pharmaceuticals | [1,2,4] TRIAZOLO [1,5-A] PYRIDINES AS KINASE INHIBITORS |
| TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
| US10554578B2 (en) | 2015-06-30 | 2020-02-04 | British Telecommunications Public Limited Company | Quality of service management in a network |
| EP3885448B1 (en) | 2016-09-02 | 2023-03-22 | New England Biolabs, Inc. | Analysis of chromatin using a nicking enzyme |
| CN111170986A (en) * | 2018-11-13 | 2020-05-19 | 北京睿熙生物科技有限公司 | Inhibitors of bruton's tyrosine kinase |
| JP2022526713A (en) | 2019-03-21 | 2022-05-26 | オンクセオ | Dbait molecule in combination with a kinase inhibitor for the treatment of cancer |
| JP2023500906A (en) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | Methods of treating cancers with acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| WO2025092989A1 (en) * | 2023-11-03 | 2025-05-08 | 泰州红云制药有限公司 | Substituted quinazoline compound, preparation method therefor, pharmaceutical combination thereof, and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004281154A1 (en) * | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
-
2007
- 2007-12-06 TW TW096146631A patent/TW200829566A/en unknown
- 2007-12-07 WO PCT/GB2007/004697 patent/WO2008068507A2/en not_active Ceased
- 2007-12-07 AR ARP070105508A patent/AR064208A1/en unknown
- 2007-12-07 PE PE2007001740A patent/PE20081351A1/en not_active Application Discontinuation
- 2007-12-07 CL CL200703557A patent/CL2007003557A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200829566A (en) | 2008-07-16 |
| WO2008068507A2 (en) | 2008-06-12 |
| WO2008068507A3 (en) | 2008-07-31 |
| PE20081351A1 (en) | 2008-11-26 |
| CL2007003557A1 (en) | 2008-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064208A1 (en) | DERIVATIVES OF PIRIDIN-3-IL-QUINAZOLINAS AS INHIBITORS OF B-RAF. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. | |
| AR055249A1 (en) | DERIVATIVES OF KINAZOLINS, PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS | |
| AR062406A1 (en) | QUINAZOLINE DERIVATIVES AS B-RAF INHIBITORS | |
| AR054183A1 (en) | DERIVATIVES OF PIRIDINCARBOXAMIDA AND ITS USE AS ANTICANCERIGEN AGENTS. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. | |
| AR061653A1 (en) | GSK3 INHIBITING COMPOUNDS (GLUCOGENO SINTASA QUINASA 3) | |
| AR070493A1 (en) | UREA HETEROCICLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF BACTERIAL INFECTIONS. | |
| AR056184A1 (en) | COMPOUNDS DERIVED FROM PIRAZOL, PHARMACEUTICAL COMPOSITION BASED ON THOSE AND ITS USE FOR THE MANUFACTURE OF MEDICINES | |
| AR056210A1 (en) | 4- (3-AMINOPIRAZOL) PYRIMIDINE FOR USE AS THYROSINE-KINASE INHIBITORS | |
| AR050545A1 (en) | DERIVATIVES OF QUINAZOLINONAS AND ITS USE AS B-RAF INHIBITORS | |
| AR053683A1 (en) | PIPERIDINE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | |
| AR056556A1 (en) | IMIDAZO (1,2-A) PIRIDINE WITH CELLULAR ANTIPROLIFERATION ACTIVITY | |
| AR053992A1 (en) | CHEMICAL COMPOUNDS WITH ANTI-TARGET ACTIVITY, A PROCEDURE FOR THEIR PREPARATION, ITS USE IN THE PREPARATION OF MEDICINES AND PHARMACEUTICAL COMPOSITION. | |
| AR063643A1 (en) | CHEMICAL COMPOUNDS DERIVED FROM QUINOLINA, A METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
| AR064130A1 (en) | DERIVATIVES OF TIAZOLS AND PIRIDINES AS ANTIBACTERIALS. PHARMACEUTICAL COMPOSITIONS. | |
| AR040408A1 (en) | DERIVATIVES OF BENZOTIADIAZEPIN, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR046779A1 (en) | DERIVATIVES OF PIRAZOL, METHODS FOR THEIR PREPARATION AND USES OF THE SAME IN THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS AND MEDICINES CONTAINING THEM WITH TRK INHIBITORY ACTIVITY FOR THE TREATMENT OR PROFILAXIS OF CANCER. | |
| AR047702A1 (en) | IMIDAZOL-5-IL-ANILINOPIRIMIDINAS AS INHIBITING AGENTS OF THE CELL PROLIFERATION | |
| AR056354A1 (en) | DERIVATIVES OF PIRAZOL, A METHOD OF PREPARATION OF THE COMPOUND, PHARMACEUTICAL COMPOSITION AND PREPARATION OF A MEDICINAL PRODUCT | |
| AR041594A1 (en) | DERIVATIVES OF 1.4 DISPOSED PIPERIDINE AND ITS USE AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | |
| AR052170A1 (en) | USEFUL PYRIMIDINE DERIVATIVES FOR ITS ANTI-PROLIFERATION CELLULAR ACTIVITY | |
| AR046616A1 (en) | USED REPLACED PIPERIDINS IN THE TREATMENT OF METABOLIC SYNDROME | |
| AR046615A1 (en) | PIRROLIDINS 3- (BENZOIL) -N-ACILATED, AS INHIBITORS OF 11-BETA-HSD1, USEFUL IN THE TREATMENT OF METABOLIC DISORDERS | |
| AR072047A1 (en) | USEFUL HETEROCICLICAL COMPOUNDS TO INHIBIT THE GIRASA DNA | |
| AR072045A1 (en) | UREA HETEROCICLIC DERIVATIVES AND METHODS TO USE THEM | |
| AR031251A1 (en) | DERIVED FROM PIRIMIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PREPARATION PROCESS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |